NO• /RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer.
Wang L., Tang W., Yang S., He P., Wang J., Gaedcke J., Ströbel P., Azizian A., Ried T., Gaida MM., Yfantis HG., Lee DH., Lal A., Van den Eynde BJ., Alexander HR., Ghadimi BM., Hanna N., Hussain SP.
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy and is refractory to available treatments. Delineating the regulatory mechanisms of metabolic reprogramming, a key event in pancreatic cancer progression, may identify candidate targets with potential therapeutic significance. We hypothesized that inflammatory signaling pathways regulate metabolic adaptations in pancreatic cancer. Metabolic profiling of tumors from PDAC patients with a high- (>median, n = 31) and low-NOS2 (inducible nitric oxide synthase;